Last reviewed · How we verify
NCT04995315
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
trial in Pyruvate Kinase Deficiency in 13 participants. Completed in 22 September 2023.
22 September 2023
Quick facts
| Lead sponsor | Agios Pharmaceuticals, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 2 July 2021 |
| Primary completion | 22 September 2023 |
| Estimated completion | 22 September 2023 |
| Sites | 3 locations across Italy, Netherlands, United States |
Conditions studied
- Pyruvate Kinase Deficiency — all drugs for Pyruvate Kinase Deficiency →
Sponsor
Agios Pharmaceuticals, Inc. — full company profile →
Who can join
18 and older, any sex, with Pyruvate Kinase Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a substudy of Study AG348-C-008, an observational, longitudinal, multicenter, global registry that aims to better understand the longitudinal clinical implications of pyruvate kinase deficiency (PK deficiency). The primary purpose of this study is to describe the cognition of participants with PK deficiency, as objectively measured by the Cogstate Brief Battery (CBB).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design.
Grace RF, van Beers EJ, Vives Corrons JL, Glader B, et al · · 2023 · cited 4× · PMID 36958777 · DOI 10.1136/bmjopen-2022-063605
Verify or expand the search:
- PubMed search for NCT04995315
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pyruvate Kinase Deficiency
Currently open trials in the same condition.
- NCT04902833 — Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms · active not recruiting
- NCT03481738 — Pyruvate Kinase Deficiency Global Longitudinal Registry · active not recruiting
Other Agios Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07075640 — A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the · Phase 1 · recruiting
- NCT06745271 — A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat · Phase 1 · completed
- NCT06648824 — Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants · Phase 1 · completed
- NCT06286033 — Single and Multiple Ascending Dose Study and Food Effect Study for AG181 · Phase 1 · completed
- NCT05610657 — A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Contro · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04995315 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Agios Pharmaceuticals, Inc.
- Last refreshed: 16 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04995315.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing